Sign in
Taking peoplePhase 1/2

A Study to Test GlaxoSmithKline's (GSK) Candidate Vaccine-GSK1437173A for Prevention of Shingles in Children With Kidney Transplant

Key facts

Who runs it
GlaxoSmithKline
Where
Belgium, France, Greece, Italy, Poland, Spain, and United Kingdom31 sites in 7 countriesChoose a country to see its sites
Status
Recruiting
Phase
Phase 1/2
People taking part
184 people, planned
Started
25 Oct 2019
Expected to end
31 Mar 2027
Type of study
Interventional, 4 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • PED-HZ/su
Record updated
27 February 2026

Who can take part

Age
1 year to 17 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 52 criteriaShow less

Who can take part

  • Subjects' parent(s)/Legally Acceptable Representative(s) [LAR(s) who, in the opinion of the investigator, can and will comply, with the requirements of the protocol
  • Written or witnessed/thumb printed informed consent obtained from the parent(s)/LAR(s) of the subject prior to performance of any study specific procedure
  • Written informed assent obtained from the subjects when applicable according to local requirements
  • A male or female between, and including, 1 and 17 years of age at the time of randomisation (Visit Day 1)
  • Body weight ≥ 6 kg/13.23 pounds
  • A subject is eligible if they meet at least one of the following criteria:; Documented previous VZV vaccination OR; Medically verified varicella (with source documentation) OR; Seropositive for VZV prior to transplantation
  • Subjects with renal transplant more than six months (180 days) prior randomization (Visit Day 1)
  • Subject who has received an ABO compatible allogeneic renal transplant (allograft)
  • Subject with stable renal function with stability defined as <20% variability between the last two creatinine measurements or based on investigator opinion after review of multiple creatinine measurements
  • Subject receiving maintenance immunosuppressive therapy for the prevention of allograft rejection for a minimum of one month (30 days) prior to randomization (Visit Day 1)
  • Female subjects of childbearing potential may be enrolled in the study, if the subject; has practiced adequate contraception for 30 days prior to Visit Day 1 and has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series

Who cannot take part

  • Previous allograft loss secondary to recurrent primary kidney disease
  • Subjects with an episode of acute allograft rejection over the six months (180 days) prior to enrolment
  • Panel Reactive Antibodies (PRA) calculated PRA (cPRA) or Calculated Reaction Frequency (cRF) score that is unknown at the time of transplant
  • VZV serostatus unknown prior to transplant
  • Atypical Haemolytic Uraemic Syndrome; Prior/Concomitant therapy
  • Use of any investigational or non-registered product other than the study vaccine during the period starting 30 days before Visit Day 1 (Day -29 to Day -1), or planned use during the study period
  • Subject in receipt of treatment for rejection during the six months (180 days) prior to enrolment
  • Use of anti-CD20 or other B-cell monoclonal antibody agents within 1 year of Visit Day 1 or planned administration during the duration of the study
  • Administration of blood products 3 months (90 days) prior to Visit Day 1 or planned administration during the duration of the study
  • Administration of immunoglobulins 6 months (180 days) prior to Visit Day 1 or planned administration of immunoglobulins during the duration of the study
  • Administration or planned administration of a vaccine within 30 days prior to Visit Day 1 up to Visit Month 2 with the exception of an inactivated or subunit influenza vaccine which may be given 8 days prior to or 14 days after Visit Day 1 and 8 days prior to or 14 days after Visit Month 1
  • Previous vaccination against HZ
  • Planned administration during the study of an HZ or varicella vaccine (including an investigational or non-registered vaccine) other than the study vaccine; Prior/Concurrent clinical study experience
  • Concurrent or planned participation in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product
  • The name of the active component(s) of these immunosuppressants must be provided in the concomitant medication listing; Other exclusions
  • Female planning to become pregnant or planning to discontinue contraceptive precautions (if of childbearing potential) between one month (30 days) prior to Visit Day 1 through two months (60 days) after Visit Month 1
  • Evidence or high suspicion, in the opinion of the investigator, of non-compliance or non-adherence to use of induction and/or maintenance immunosuppressive therapies
  • Failure to fully complete the 7-day pre-vaccination diary card distributed at the Pre-vaccination visit; Completion must cover the 7 days immediately prior to randomisation (Visit Day 1); Completion is defined as a minimum of 6 days completed; Subjects with less than 6 days completed may be offered a new date for Visit Day 1 and the opportunity to comply with the completion of the 7-day pre-vaccination diary card prior to the new planned Visit Day 1
  • Medical conditions
  • Any primary kidney disease with a high incidence of recurrent primary kidney disease within the allograft
  • Evidence of recurrent primary kidney disease within the current allograft
  • History of more than one organ transplanted (that is, kidney-liver, simultaneous double kidney or kidney-other organ(s) transplanted)
  • Subjects with advanced chronic kidney disease
  • History of unstable or progressive neurological disorder
  • Any autoimmune disease, with the following exceptions which do not constitute an exclusion criterion:; IgA nephropathy; Rapidly progressive glomerulonephritis; Membranous glomerulonephritis; Idiopathic Type I membranoproliferative glomerulonephritis; Diabetes mellitus (type 1 and 2) with diabetic nephropathy
  • Confirmed or suspected Human Immunodeficiency Virus or primary immunodeficiency disease
  • Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the subject due to participation in the study
  • History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine
  • Any condition which, in the judgement of the investigator would make intramuscular injection unsafe
  • Evidence of significant proteinuria (≥ 200 g/mol creatinine) believed to be of renal origin (an example of non-renal origin is proteinuria from mucus in a reconstructed bladder)
  • Subjects ≤ 5 years of age with a history of one or more simple or complex febrile seizures
  • Subjects > 5 years with history of one or more complex febrile seizures
  • Subjects without multiple dialysis options in the event acute or chronic dialysis needed
  • Occurrence of a varicella or HZ episode by clinical history within the 6 months (180 days) preceding Visit Day 1
  • Varicella vaccination within the 6 months (180 days) preceding Visit Day 1
  • available locally through compassionate use programs,
  • submitted for and pending local/country registration,
  • approved and registered for use in other countries with well-documented Summary of Product Characteristics or Prescribing Information
  • Child in care
  • Pregnant or lactating female
  • Any study personnel or their immediate dependants, family, or household member

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 1 and 17 years old?

This trial has no sites in United States.

It has sites in 7 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

The purpose of this study is to evaluate the reactogenicity, safety and immunogenicity of 2 doses of PED-HZ/su, GSK's vaccine candidate for the prevention of Herpes Zoster (HZ) in immunocompromised paediatric renal transplant recipients aged 1-17 years

The 4 groups in the trial

  • PED-HZ/su 12-17 GroupTreatment being tested

    Paediatric renal transplant recipients aged 12 to 17 years old, receiving 2 doses of the investigational vaccine (PED HZ/su)

    Treatment: PED-HZ/su

  • Control 12-17 GroupNo study treatment, for comparison

    Paediatric renal transplant recipients aged 12 to 17 years old, not receiving the investigational vaccine but being treated according to the local standard of care

  • PED-HZ/su 1-11 GroupTreatment being tested

    Paediatric renal transplant recipients aged 1 to 11 years old, receiving 2 doses of the investigational vaccine (PED HZ/su). Enrolment into this group will be in a staggered manner. Following enrolment into the PED-HZ/su 12-17 group, a safety evaluation of data collected up to visit month 2 will be performed. Upon favourable outcome of the evaluation, enrolment into this group will begin.

    Treatment: PED-HZ/su

  • Control 1-11 GroupNo study treatment, for comparison

    Paediatric renal transplant recipients aged 1 to 11 years old, not receiving the investigational vaccine but being treated according to the local standard of care

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Reactogenicity, Safety and Immunogenicity Study of GSK's Paediatric Herpes Zoster Subunit Candidate Vaccine (PED-HZ/su) GSK143713A in Immunocompromised Paediatric Renal Transplant Recipients
Criteria questions
Built from NCT04006808, who can take part
Publications
Record updated
27 February 2026